Literature DB >> 19052699

Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Bo Wang1, Roland Tisch.   

Abstract

Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin producing beta cells are destroyed. Antigen-based immunotherapy provides an approach to selectively tolerize pathogenic beta cell-specific T cells, while leaving the remainder of the immune system intact. In this article, we discuss our group's experience in defining the parameters that impact the efficacy of beta cell antigen "vaccination" for the prevention and treatment of T1D.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19052699     DOI： 10.1007/s12026-008-8090-5

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


  115 in total

Review 1.  Prediction of type 1 diabetes: the natural history of the prediabetic period.

Authors:  George S Eisenbarth
Journal:  Adv Exp Med Biol       Date:  2004       Impact factor: 2.622

2.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes.

Authors:  J A Shizuru; C Taylor-Edwards; B A Banks; A K Gregory; C G Fathman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

Review 3.  T cell tolerance induced by therapeutic antibodies.

Authors:  Stephen P Cobbold
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera.

Authors:  Sofia Casares; Alicia Hurtado; Robert C McEvoy; Adelaida Sarukhan; Harald von Boehmer; Teodor-Doru Brumeanu
Journal:  Nat Immunol       Date:  2002-02-25       Impact factor: 25.606

5.  More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice.

Authors:  Christian Seifarth; Shannon Pop; Bo Liu; Carmen P Wong; Roland Tisch
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

6.  Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes.

Authors:  Shannon M Pop; Carmen P Wong; Donna A Culton; Stephen H Clarke; Roland Tisch
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

7.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

8.  In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha.

Authors:  S V Pakala; M Chivetta; C B Kelly; J D Katz
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

9.  Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells.

Authors:  A Bendelac; C Carnaud; C Boitard; J F Bach
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes.

Authors:  Kristin V Tarbell; Sayuri Yamazaki; Kara Olson; Priscilla Toy; Ralph M Steinman
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307
View more
  5 in total

Review 1.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

Review 2.  Current and emerging options for the drug treatment of narcolepsy.

Authors:  Alberto K De la Herrán-Arita; Fabio García-García
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

4.  IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease.

Authors:  Eva d'Hennezel; Mara Kornete; Ciriaco A Piccirillo
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

5.  Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination.

Authors:  Li Li; Zuoan Yi; Bo Wang; Roland Tisch
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.